U
PGNX

UBS’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

UBS’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5,500
Closed -$29K – 11008
2013
Q4 		$29K Buy
+5,500
New +$24.2K ﹤0.01% 7697

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS's PGNX Position: Q3 2014 in Review

UBS reduced its Progenics Pharmaceuticals Inc (PGNX) stake by 13% in Q3 2014, selling an estimated $7.02K and leaving 9,744 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #6808.

UBS first reported a position in PGNX in Q2 2013 and has held it in 6 quarters since. The position peaked at $65K in Q3 2013. 78 funds tracked by Wall St. Rank hold PGNX as of Q3 2014.

  • UBS held 9,744 shares of Progenics Pharmaceuticals Inc worth $51K as of Q3 2014.
  • UBS sold 1,408 Progenics Pharmaceuticals Inc shares in Q3 2014, an estimated $7.02K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6808 holding.
  • UBS first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Progenics Pharmaceuticals Inc position peaked at $65K in Q3 2013.
  • 78 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.